Bausch Health is rumored to be looking to sell its Bausch + Lomb business, which will ease bankruptcy concerns and upgrade ...

Federal Reserve's rate cut boosted tech, construction, industrial, machinery, and financial sectors. Top-performing mid-cap ...

The Financial Times reported Bausch + Lomb is in talks with advisors to potentially sell itself. It had formerly sought to spin off from parent Bausch Health in a stock-for-stock deal. But Bausch ...

NEWS Bausch & Lomb Sues Competition Over Copycat Formulation and 'Confusingly Similar' Product Name This suit was surfaced by Law.com Radar, ALM's source for immediate alerting on just filed cases ...

Analyst Glen Santangelo of Jefferies reiterated a Buy rating on Bausch Health Companies (BHC – Research Report), reducing the price ...

Investing.com -- Bausch + Lomb (NYSE:BLCO) is exploring a potential sale as part of an effort to resolve issues related to its separation from parent company Bausch Health, which is burdened with ...

Analyst Larry Biegelsen from Wells Fargo maintained a Buy rating on Bausch + Lomb Corporation (BLCO – Research Report) and keeping the price target at $23.00. Larry Biegelsen has given his Buy ...

Bausch + Lomb BLCO shares ended the last trading session 14.5% higher at $17.80. The jump came on an impressive volume with a higher-than-average number of shares changing hands in the session.

Bausch + Lomb Corp. shares rose the most ever following a report that the eye care company is considering selling itself to disentangle from its debt-laden parent company. The Financial Times ...

Eyecare company is working with Goldman Sachs on a deal that would extricate it from its indebted parent, the Financial Times reported The stock of eyecare company Bausch + Lomb Corp. was up 14%on ...